Uncategorized

FDA’s cell and gene therapy head steps down after 1 year

Published

on

Vijay Kumar, acting director of CBER’s Office of Therapeutic Products, will leave his role at a tumultuous time for the FDA.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version